A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors

被引：0
|
作者：
Autumn J. McRee
Janine M. Davies
Hanna G. Sanoff
Richard M. Goldberg
Stephen Bernard
E. Claire Dees
Kimberly Keller
Anastasia Ivanova
Bert H. O’Neil
机构：
[1] The University of North Carolina at Chapel Hill,Department of Medicine, Division of Hematology/Oncology, School of Medicine
[2] BC Cancer Agency,School of Medicine
[3] The Ohio State University,School of Medicine
[4] Indiana University,Department of Medicine
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
Everolimus; 5-Fluorouracil; Oxaliplatin; Panitumumab; Metastatic colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：117 / 123
页数：6
相关论文
共 50 条
  • [1] A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors
    McRee, Autumn J.
    Davies, Janine M.
    Sanoff, Hanna G.
    Goldberg, Richard M.
    Bernard, Stephen
    Dees, E. Claire
    Keller, Kimberly
    Ivanova, Anastasia
    O'Neil, Bert H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 117 - 123
  • [2] mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale
    Nagata, Naoki
    Mishima, Hideyuki
    Kurosawa, Shuichi
    Oba, Koji
    Sakamoto, Junichi
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : 154 - +
  • [3] Sunitinib in combination with mFOLFOX6 chemotherapy in patients with advanced solid tumors: A phase I study
    Leong, S.
    Eckhardt, S.
    Chan, E.
    Chow, L.
    VerMeulen, W.
    Camidge, D.
    Rothenberg, M.
    Chow Maneval, E.
    Chao, R.
    Lockhart, A.
    ANNALS OF ONCOLOGY, 2007, 18 : VII123 - VII123
  • [4] A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancer
    Belhadef, S.
    Arab, A.
    Belmadi, M.
    Beninal, M.
    Bacha, N.
    Abdallah, R.
    Mechta, K.
    Dahmane, A.
    Mahfouf, H.
    Oukkal, M.
    Bouzid, K.
    Faraqun, S.
    Bentabak, K.
    Younes, S. Ait
    ANNALS OF ONCOLOGY, 2020, 31 : S92 - S92
  • [5] Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
    Takahashi, Takao
    Ishida, Kazuyuki
    Emi, Yasunori
    Sakamoto, Michiie
    Imura, Johji
    Aishima, Shinichi
    Muro, Kei
    Uetake, Hiroyuki
    Oki, Eiji
    Katayose, Yu
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    CANCERS, 2022, 14 (18)
  • [6] A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer
    M. Michael
    J. Zalcberg
    P. Gibbs
    L. Lipton
    M. Gouillou
    M. Jefford
    G. McArthur
    M. Copeman
    K. Lynch
    N. C. Tebbutt
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 321 - 330
  • [7] Randomized phase II study of maintenance treatment with 5-FU/FA plus panitumumab vs 5-FU/FA alone after induction (mFOLFOX6 plus panitumumab) in patients with RASWT metastatic colorectal cancer
    Modest, D. P.
    Kasper, S.
    Stintzing, S.
    Prasnikar, N.
    Mueller, L.
    Caca, K.
    Goekkurt, E.
    von Weikersthal, L. Fischer
    Kopp, H. -G.
    Trarbach, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Histopathologic evaluation of patients with liver-limited metastatic colorectal cancer receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus cetuximab: The ATOM trial
    Emi, Y.
    Yamanaka, T.
    Muro, K.
    Uetake, H.
    Oki, E.
    Takahashi, T.
    Katayose, Y.
    Yoshida, K.
    Sakamoto, M.
    Aishima, S.
    Ishida, K.
    Imura, J.
    Unno, M.
    Hyodo, I.
    Tomita, N.
    Sugihara, K.
    Maehara, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
    Eiji Oki
    Yasunori Emi
    Takeharu Yamanaka
    Hiroyuki Uetake
    Kei Muro
    Takao Takahashi
    Takeshi Nagasaka
    Etsuro Hatano
    Hitoshi Ojima
    Dai Manaka
    Tetsuya Kusumoto
    Yu Katayose
    Toshiyoshi Fujiwara
    Kazuhiro Yoshida
    Michiaki Unno
    Ichinosuke Hyodo
    Naohiro Tomita
    Kenichi Sugihara
    Yoshihiko Maehara
    British Journal of Cancer, 2019, 121 : 222 - 229
  • [10] A Phase I/II, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer
    Van Cutsem, E.
    Prenen, H.
    Guillen-Ponce, C.
    Bennouna, J.
    Di Benedetto, M.
    Bouche, O.
    Staines, H.
    Oum'Hamed, Z.
    Studeny, M.
    Capdevila, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : 8 - 9
12345